-
Something wrong with this record ?
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
VS. Hoffmann, M. Baccarani, J. Hasford, D. Lindoerfer, S. Burgstaller, D. Sertic, P. Costeas, J. Mayer, K. Indrak, H. Everaus, P. Koskenvesa, J. Guilhot, G. Schubert-Fritschle, F. Castagnetti, F. Di Raimondo, S. Lejniece, L. Griskevicius, N....
Language English Country England, Great Britain
Document type Journal Article, Observational Study, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Medline Complete (EBSCOhost)
from 1997-01-01 to 2015-11-30
Nursing & Allied Health Database (ProQuest)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2000-01-01 to 1 year ago
PubMed
25783795
DOI
10.1038/leu.2015.73
Knihovny.cz E-resources
- MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive epidemiology MeSH
- Adult MeSH
- Incidence MeSH
- Cohort Studies MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Follow-Up Studies MeSH
- Prognosis MeSH
- Registries statistics & numerical data MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe MeSH
This population-based registry was designed to provide robust and updated information on the characteristics and the epidemiology of chronic myeloid leukemia (CML). All cases of newly diagnosed Philadelphia positive, BCR-ABL1+ CML that occurred in a sample of 92.5 million adults living in 20 European countries, were registered over a median period of 39 months. 94.3% of the 2904 CML patients were diagnosed in chronic phase (CP). Median age was 56 years. 55.5% of patients had comorbidities, mainly cardiovascular (41.9%). High-risk patients were 24.7% by Sokal, 10.8% by EURO, and 11.8% by EUTOS risk scores. The raw incidence increased with age from 0.39/100,000/year in people 20-29 years old to 1.52 in those >70 years old, and showed a maximum of 1.39 in Italy and a minimum of 0.69 in Poland (all countries together: 0.99). The proportion of Sokal and Euro score high-risk patients seen in many countries indicates that trial patients were not a positive selection. Thus from a clinical point of view the results of most trials can be generalized to most countries. The incidences observed among European countries did not differ substantially. The estimated number of new CML cases per year in Europe is about 6370.
3 Medizinische Klinik University of Heidelberg in Mannheim Mannheim Germany
Department of Hematology and Bone Marrow Transplantation Tartu University Hospital Tartu Estonia
Department of Hematology and Oncology L and A University of Bologna Bologna Italy
Department of Hematology and Transplantation Medical University of Gdansk Gdansk Poland
Department of Hematology Jagellonian University Hospital Krakow Poland
Department of Hematology Oncology University Hospital Palacky University Olomouc Czech Republic
Department of Hematology University Clinical Centre Ljubljana Slovenia
Department of Hematology University Hospital Bratislava Slovakia
Department of Hematology VU University Medical Center Amsterdam The Netherlands
Department of Internal Medicine 4 Haematology and Oncology Klinikum Wells Grieskirchen Wells Austria
Department of Internal Medicine Hematooncology Masaryk University Hospital Brno Czech Republic
Department of Internal Medicine University of Uppsala Uppsala Sweden
Department of Medicine Division of Hematology University Hospital Center Zagreb Croatia
Department of Specialistic Diagnostic and Experimental Medicine University of Bologna Bologna Italy
Division of Hematology Azienda Policlinico OVE University of Catania Catania Italy
FSBI Hematology Research Center of Healthcare Ministry of Russian Federation Moscow Russia
Hematology and Research Institute Hospital de la Princesa Madrid Spain
INSERM CIC 1402 CHU Poitiers France
Institut za Haematologiju Clinical Center of Serbia University of Belgrade Belgrade Serbia
Institute of Hematology St Petersburg State Medical University St Petersburg Russian Federation
Institute of Translational Medicine Royal Liverpool University Hospital Liverpool UK
Munich Cancer Registry Ludwig Maximilians Universitaet Munich Germany
National Hematology Centre Riga Eastern Clinical University Hospital Riga Latvia
Novartis Oncology Europe Origgio Italy
The Karaiskakio Foundation Nicosia Cyprus
Vilnius University Hospital Santariskiu Klinikos Vilnius Lithuania
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031428
- 003
- CZ-PrNML
- 005
- 20190412092702.0
- 007
- ta
- 008
- 151005s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/leu.2015.73 $2 doi
- 035 __
- $a (PubMed)25783795
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Hoffmann, V S $u Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet, Munich, Germany.
- 245 14
- $a The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries / $c VS. Hoffmann, M. Baccarani, J. Hasford, D. Lindoerfer, S. Burgstaller, D. Sertic, P. Costeas, J. Mayer, K. Indrak, H. Everaus, P. Koskenvesa, J. Guilhot, G. Schubert-Fritschle, F. Castagnetti, F. Di Raimondo, S. Lejniece, L. Griskevicius, N. Thielen, T. Sacha, A. Hellmann, AG. Turkina, A. Zaritskey, A. Bogdanovic, Z. Sninska, I. Zupan, JL. Steegmann, B. Simonsson, RE. Clark, A. Covelli, G. Guidi, R. Hehlmann,
- 520 9_
- $a This population-based registry was designed to provide robust and updated information on the characteristics and the epidemiology of chronic myeloid leukemia (CML). All cases of newly diagnosed Philadelphia positive, BCR-ABL1+ CML that occurred in a sample of 92.5 million adults living in 20 European countries, were registered over a median period of 39 months. 94.3% of the 2904 CML patients were diagnosed in chronic phase (CP). Median age was 56 years. 55.5% of patients had comorbidities, mainly cardiovascular (41.9%). High-risk patients were 24.7% by Sokal, 10.8% by EURO, and 11.8% by EUTOS risk scores. The raw incidence increased with age from 0.39/100,000/year in people 20-29 years old to 1.52 in those >70 years old, and showed a maximum of 1.39 in Italy and a minimum of 0.69 in Poland (all countries together: 0.99). The proportion of Sokal and Euro score high-risk patients seen in many countries indicates that trial patients were not a positive selection. Thus from a clinical point of view the results of most trials can be generalized to most countries. The incidences observed among European countries did not differ substantially. The estimated number of new CML cases per year in Europe is about 6370.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a chronická myeloidní leukemie $x epidemiologie $7 D015464
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a registrace $x statistika a číselné údaje $7 D012042
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Baccarani, M $u Department of Hematology and Oncology L. and A., University of Bologna, Bologna, Italy.
- 700 1_
- $a Hasford, J $u Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet, Munich, Germany.
- 700 1_
- $a Lindoerfer, D $u Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet, Munich, Germany.
- 700 1_
- $a Burgstaller, S $u Department of Internal Medicine IV, Haematology and Oncology, Klinikum Wells-Grieskirchen, Wells, Austria.
- 700 1_
- $a Sertic, D $u Department of Medicine, Division of Hematology, University Hospital Center, Zagreb, Croatia.
- 700 1_
- $a Costeas, P $u The Karaiskakio Foundation, Nicosia, Cyprus.
- 700 1_
- $a Mayer, J $u Department of Internal Medicine - Hematooncology, Masaryk University Hospital, Brno, Czech Republic.
- 700 1_
- $a Indrák, Karel, $u Department of Hematology-Oncology, University Hospital, Palacky University, Olomouc, Czech Republic. $d 1947- $7 jn20000401162
- 700 1_
- $a Everaus, H $u Department of Hematology and Bone Marrow Transplantation, Tartu University Hospital, Tartu, Estonia.
- 700 1_
- $a Koskenvesa, P $u Hematology Research Unit, Helsinki University Central Hospital and Hematology Research Unit, Biomedicum, Helsinki, Finland.
- 700 1_
- $a Guilhot, J $u INSERM CIC 1402, CHU, Poitiers, France.
- 700 1_
- $a Schubert-Fritschle, G $u Munich Cancer Registry, Ludwig-Maximilians-Universitaet, Munich, Germany.
- 700 1_
- $a Castagnetti, F $u Department of Specialistic, Diagnostic and Experimental Medicine, University of Bologna, Bologna, Italy.
- 700 1_
- $a Di Raimondo, F $u Division of Hematology, Azienda Policlinico-OVE, University of Catania, Catania, Italy.
- 700 1_
- $a Lejniece, S $u National Hematology Centre, Riga Eastern Clinical University Hospital, Riga, Latvia.
- 700 1_
- $a Griskevicius, L $u Vilnius University Hospital, Santariskiu Klinikos, Vilnius, Lithuania.
- 700 1_
- $a Thielen, N $u Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
- 700 1_
- $a Sacha, T $u Department of Hematology, Jagellonian University Hospital, Krakow, Poland.
- 700 1_
- $a Hellmann, A $u Department of Hematology and Transplantation, Medical University of Gdansk, Gdansk, Poland.
- 700 1_
- $a Turkina, A G $u FSBI Hematology Research Center of Healthcare Ministry of Russian Federation, Moscow, Russia.
- 700 1_
- $a Zaritskey, A $u Institute of Hematology, St. Petersburg State Medical University, St. Petersburg, Russian Federation.
- 700 1_
- $a Bogdanovic, A $u Institut za Haematologiju, Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia.
- 700 1_
- $a Sninska, Z $u Department of Hematology, University Hospital, Bratislava, Slovakia.
- 700 1_
- $a Zupan, I $u Department of Hematology, University Clinical Centre, Ljubljana, Slovenia.
- 700 1_
- $a Steegmann, J-L $u Hematology & Research Institute, Hospital de la Princesa, Madrid, Spain.
- 700 1_
- $a Simonsson, B $u Department of Internal Medicine, University of Uppsala, Uppsala, Sweden.
- 700 1_
- $a Clark, R E $u Institute of Translational Medicine, Royal Liverpool University Hospital, Liverpool, UK.
- 700 1_
- $a Covelli, A $u Novartis Oncology Europe, Origgio, Italy.
- 700 1_
- $a Guidi, G $u Novartis Oncology Europe, Origgio, Italy.
- 700 1_
- $a Hehlmann, Rüdiger, $d 1941- $7 xx0110206 $u III. Medizinische Klinik, University of Heidelberg in Mannheim, Mannheim, Germany.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 29, č. 6 (2015), s. 1336-43
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25783795 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20190412092720 $b ABA008
- 999 __
- $a ok $b bmc $g 1092304 $s 914554
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 29 $c 6 $d 1336-43 $e 20150318 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20151005
